Rein Therapeutics (RNTX) Competitors

Rein Therapeutics logo
$0.36 -0.04 (-10.90%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.38 +0.03 (+7.18%)
As of 09:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RNTX vs. GALT, ARTV, PLX, CGEN, and ADCT

Should you buy Rein Therapeutics stock or one of its competitors? Rein Therapeutics's main competitors and comparable companies include Galectin Therapeutics (GALT), Artiva Biotherapeutics (ARTV), Protalix BioTherapeutics (PLX), Compugen (CGEN), and ADC Therapeutics (ADCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rein Therapeutics compare to Galectin Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Rein Therapeutics and Rein Therapeutics both had 4 articles in the media. Galectin Therapeutics' average media sentiment score of 1.20 beat Rein Therapeutics' score of 1.17 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rein Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Galectin Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rein TherapeuticsN/AN/A-$49.87M-$1.72N/A
Galectin TherapeuticsN/AN/A-$30.84M-$0.43N/A

Rein Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by insiders. Comparatively, 53.0% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Rein TherapeuticsN/A N/A -69.69%
Galectin Therapeutics N/A N/A -138.82%

Rein Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 1,583.50%. Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 278.01%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Rein Therapeutics is more favorable than Galectin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Galectin Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Rein Therapeutics beats Galectin Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Rein Therapeutics compare to Artiva Biotherapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Rein Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.67, suggesting that its share price is 167% more volatile than the broader market.

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than Rein Therapeutics. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 4 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.17 beat Artiva Biotherapeutics' score of 0.54 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rein Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Artiva Biotherapeutics
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rein Therapeutics has higher earnings, but lower revenue than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rein TherapeuticsN/AN/A-$49.87M-$1.72N/A
Artiva Biotherapeutics$250K763.20-$83.86M-$2.98N/A

Rein Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 1,583.50%. Artiva Biotherapeutics has a consensus target price of $24.80, suggesting a potential upside of 542.49%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Rein Therapeutics is more favorable than Artiva Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Artiva Biotherapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

90.9% of Rein Therapeutics shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by company insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Rein Therapeutics' return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rein TherapeuticsN/A N/A -69.69%
Artiva Biotherapeutics N/A -45.32%-41.38%

Summary

Rein Therapeutics beats Artiva Biotherapeutics on 7 of the 12 factors compared between the two stocks.

How does Rein Therapeutics compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Rein Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Rein Therapeutics' return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protalix BioTherapeutics-21.03% -30.89% -11.74%
Rein Therapeutics N/A N/A -69.69%

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Protalix BioTherapeutics has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

In the previous week, Protalix BioTherapeutics had 6 more articles in the media than Rein Therapeutics. MarketBeat recorded 10 mentions for Protalix BioTherapeutics and 4 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.17 beat Protalix BioTherapeutics' score of -0.05 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protalix BioTherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rein Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Protalix BioTherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 316.67%. Rein Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 1,583.50%. Given Rein Therapeutics' higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Protalix BioTherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protalix BioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Protalix BioTherapeutics has higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protalix BioTherapeutics$84.69M2.87$8.31M$0.2511.52
Rein TherapeuticsN/AN/A-$49.87M-$1.72N/A

Summary

Rein Therapeutics beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Compugen?

Compugen (NASDAQ:CGEN) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Compugen currently has a consensus target price of $5.00, indicating a potential upside of 147.52%. Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 1,583.50%. Given Rein Therapeutics' higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Compugen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compugen
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Compugen has higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$72.76M2.62$35.34M$0.395.18
Rein TherapeuticsN/AN/A-$49.87M-$1.72N/A

In the previous week, Compugen had 5 more articles in the media than Rein Therapeutics. MarketBeat recorded 9 mentions for Compugen and 4 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.17 beat Compugen's score of 0.92 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compugen
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rein Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

12.2% of Compugen shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Compugen has a beta of 2.85, suggesting that its stock price is 185% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

Compugen has a net margin of 47.90% compared to Rein Therapeutics' net margin of 0.00%. Compugen's return on equity of 39.30% beat Rein Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Compugen47.90% 39.30% 25.51%
Rein Therapeutics N/A N/A -69.69%

Summary

Compugen beats Rein Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Rein Therapeutics compare to ADC Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Rein Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by insiders. Comparatively, 5.1% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rein Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -95.73%.

Company Net Margins Return on Equity Return on Assets
Rein TherapeuticsN/A N/A -69.69%
ADC Therapeutics -95.73%N/A -28.26%

Rein Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rein TherapeuticsN/AN/A-$49.87M-$1.72N/A
ADC Therapeutics$81.36M2.34-$142.62M-$0.52N/A

In the previous week, Rein Therapeutics had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Rein Therapeutics and 1 mentions for ADC Therapeutics. Rein Therapeutics' average media sentiment score of 1.17 beat ADC Therapeutics' score of 0.53 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rein Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADC Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rein Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 1,583.50%. ADC Therapeutics has a consensus price target of $5.00, indicating a potential upside of 269.00%. Given Rein Therapeutics' higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than ADC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
ADC Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

ADC Therapeutics beats Rein Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Rein Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNTX vs. The Competition

MetricRein TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$34.51M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-0.2326.7033.9728.44
Price / SalesN/A15.788.495.70
Price / Cash7.0022.9521.0121.90
Price / Book-0.334.184.453.72
Net Income-$49.87M-$24.15M$3.52B$393.10M
7 Day Performance-41.19%-7.79%-5.94%-5.77%
1 Month Performance-39.62%-5.95%-4.58%-7.14%
1 Year Performance-70.79%-8.08%-1.95%-7.47%

Rein Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNTX
Rein Therapeutics
2.1982 of 5 stars
$0.36
-10.9%
$6.00
+1,583.5%
-70.8%$34.51MN/AN/A10
GALT
Galectin Therapeutics
1.938 of 5 stars
$3.32
+5.7%
$11.00
+231.3%
-51.5%$218.65MN/AN/A9
ARTV
Artiva Biotherapeutics
3.0052 of 5 stars
$4.22
+1.6%
$24.80
+488.4%
+10.0%$206.07M$250KN/A115
PLX
Protalix BioTherapeutics
2.7873 of 5 stars
$2.53
-0.6%
$12.00
+375.2%
+52.4%$203.44M$80.62MN/A226
CGEN
Compugen
3.5756 of 5 stars
$2.11
+7.9%
$5.00
+136.5%
+27.0%$197.14M$74.00M5.4975

Related Companies and Tools


This page (NASDAQ:RNTX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners